Biotech heads towards big catalysts

Following our analysis of key upcoming data for big pharma, Evaluate Vantage continues with a look at the important clinical results expected for biotech companies with a market cap of at least $1bn.

Fibrogen is hoping to make a mark in idiopathic pulmonary fibrosis with pamrevlumab, while Travere is gearing up to release longer term data on Filspari in focal segmental glomerulosclerosis. Elsewhere, Argenx will report data on its subcutaneous version of Vyvgart in an important new commercial opportunity for the anti-FcRn class, while Bavarian hopes to follow big pharma into the respiratory syncytial virus vaccine space.